CLR 1404 I-131

Drug Profile

CLR 1404 I-131

Alternative Names: (131)I-CLR1404; 131-I-NM404; 131I-CLR1404; CLR 131; CLR1404-I-131; HOT; I-131-CLR1404; NM-404

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Antineoplastics; Drug conjugates; Phospholipid ethers; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma; Rhabdomyosarcoma; Neuroblastoma; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Multiple myeloma
  • Phase I/II Non-small cell lung cancer
  • Preclinical Head and neck cancer; Neuroblastoma
  • No development reported Solid tumours

Most Recent Events

  • 13 Aug 2018 CLR 1404 I-131 receives Rare Paediatric Disease Designation from the US FDA for Ewing's sarcoma
  • 18 Jul 2018 Updated efficacy data from a phase IIb trial in Haematological malignancies released by Cellectar Biosciences
  • 17 Jul 2018 Efficacy data from a phase II trial in Haematological malignancies released by Cellectar Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top